InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,459.10
(
1.11%
)
US TECH 100
18,514.00
(
1.00%
)
Dow Jones
40,589.34
(
1.64%
)
Brent Oil
79.75
(
0.00%
)
Bitcoin
67,681.25
(
-0.18%
)
Post# of 376163
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

madrose1

Send PM Follow Ignore
Followers 283
Posts 47139
Boards Moderated 10
Alias Born 04/07/2001

madrose1

Member Level

Re: None

Tuesday, 04/10/2007 12:03:55 PM

Tuesday, April 10, 2007 12:03:55 PM

Post# of 376163
IMCL ouchie -->Imclone-IMCL & Bristol-Myers-BMY say Erbitux Study did not meet primary endpoint
ImClone Systems Incorporated and Bristol-Myers Squibb Company announced that a Phase III study of ERBITUX(R) plus gemcitabine in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival. :theflyonthewall

Know how to make God laugh?
Tell Her your plans ....

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up